[The treatment of patients with ischemic heart disease and significant disorder of left ventricular function]

Likars'Ka Sprava
|April 1, 1992
PubMed

Insights

Aortocoronary shunting surgery improved heart function and survival in patients with ischemic heart disease compared to medical treatment alone. Surgical intervention reduced complications such as myocardial infarction and heart failure.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Ischemic Heart Disease Research

Background:

  • Severe left ventricular contractile dysfunction is a hallmark of advanced ischemic heart disease.
  • Medical management of ischemic heart disease with severe left ventricular dysfunction often yields suboptimal outcomes.
  • Aortocoronary shunting is a surgical revascularization technique aimed at improving myocardial perfusion.

Purpose of the Study:

  • To compare the efficacy of aortocoronary shunting versus medical treatment in patients with ischemic heart disease and severe left ventricular dysfunction.
  • To evaluate the impact of surgical intervention on myocardial contractile capacity and long-term survival.
  • To assess the incidence of adverse cardiac events in both treatment groups.

Main Methods:

  • A cohort of 71 patients with coronarographically verified ischemic heart disease and severe left ventricular contractile disorders was studied.
  • Thirty-eight patients underwent aortocoronary shunting.
  • The remaining patients received medical treatment.

Main Results:

  • Aortocoronary shunting significantly improved myocardial contractile capacity compared to medical therapy.
  • Patients undergoing surgery demonstrated longer survival rates.
  • Medical treatment was associated with a higher incidence of myocardial infarctions and cardiac insufficiency, often leading to fatal outcomes.

Conclusions:

  • Aortocoronary shunting offers superior clinical benefits for patients with ischemic heart disease and severe left ventricular dysfunction.
  • Surgical revascularization improves cardiac function and survival while reducing major adverse cardiac events.
  • Medical management alone carries a higher risk of complications and mortality in this patient population.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...